WordNet

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

Use of conivaptan for management of hyponatremia following surgery for Cushing's disease.

Breshears JD, Jiang B, Rowland NC, Kunwar S, Blevins LS.SourceCalifornia Center for Pituitary Disorders, Department of Neurological Surgery, University of California, San Francisco, San Francisco, CA, USA. Electronic address: breshearsj@neurosurg.ucsf.edu.
Clinical neurology and neurosurgery.Clin Neurol Neurosurg.2013 Aug 27. pii: S0303-8467(13)00322-3. doi: 10.1016/j.clineuro.2013.08.019. [Epub ahead of print]
BACKGROUND: Hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a common osmoregulatory complication following surgery for Cushing's disease. Conventional management includes water restriction and sodium repletion, however this regimen does not address the underly
PMID 24041963

Lehrich RW, Ortiz-Melo DI, Patel MB, Greenberg A.SourceDivision of Nephrology, Department of Medicine, Duke University Medical Center, Durham, NC 27705, USA.
American journal of kidney diseases : the official journal of the National Kidney Foundation.Am J Kidney Dis.2013 Aug;62(2):364-76. doi: 10.1053/j.ajkd.2013.01.034. Epub 2013 May 29.
Hyponatremia, the most commonly encountered electrolyte abnormality, affects as many as 30% of hospitalized patients. It is a powerful predictor of poor outcomes, especially in patients with congestive heart failure or cirrhosis. The failure to excrete electrolyte-free water that results from persis
PMID 23725974

Pharmaceutical development of a parenteral formulation of conivaptan hydrochloride.

Ban K, Sonohara R, Yoshida M, Sako K, Uchida S, Namiki N.SourcePharmaceutical Research and Technology Laboratories, Astellas Pharma Inc., Yaizu, Shizuoka, Japan;
PDA journal of pharmaceutical science and technology / PDA.PDA J Pharm Sci Technol.2013 Jul 1;67(4):336-53. doi: 10.5731/pdajpst.2013.00926.
Conivaptan hydrochloride injection (Vaprisol®) was developed for the treatment of hyponatremia. Because the drug is very slightly soluble in water, pH control and cosolvency techniques were used to achieve the optimum concentration required for clinical trial material. Stability studies on retained
PMID 23872444

New Topics in Vasopressin Receptors and Approach to Novel Drugs : Research and Development of Conivaptan Hydrochloride (YM087), a Drug for the Treatment of Hyponatremia

Arai Yukinori,Fujimori Akira,Sasamata Masao [他],MIYATA Keiji
Journal of pharmacological sciences 109(1), 53-59, 2009-01-20
… Conivaptan hydrochloride (YM087) is a novel dual AVP–R antagonist for AVP-R types 1a (V1a) and V2-R. … Conivaptan hydrochloride improved the plasma sodium concentration and plasma osmolality in hyponatremic rats, and its effectiveness was demonstrated in hyponatremic patients. …
NAID 10025733636

A Novel Vasopressin Dual V_<1A>/V_2 Receptor Antagonist, Conivaptan Hydrochloride, Improves Hyponatremia in Rats with Syndrome of Inappropriate Secretion of Antidiuretic Hormone (SIADH)(Pharmacology)

Wada Koh-ichi,Matsukawa Utane,Fujimori Akira [他],ARAI Yukinori,SUDOH Katsumi,SASAMATA Masao,MIYATA Keiji
Biological & pharmaceutical bulletin 30(1), 91-95, 2007-01-01
… We investigated the effects of intravenous administration of conivaptan hydrochloride, a dual vasopressin V_<1A> … In this experimental model, intravenous administration of conivaptan (0.1, 1mg/kg) significantly increased blood sodium concentration and plasma osmolality. …
NAID 110006153273

Nonpeptide Arginine Vasopressin Antagonists for Both V_<1A> and V_2 Receptors : Synthesis and Pharmacological Properties of 4'-(1,4,5,6-Tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)benzanilide Derivatives and 4'-(5,6-Dihydro-4H-thiazolo[5,4-d][1]benzoazepine-6-carbonyl)benzanilide Derivatives

Matsuhisa Akira,Taniguchi Nobuaki,Koshio Hiroyuki [他],YATSU Takeyuki,TANAKA Akihiro
Chemical & pharmaceutical bulletin 48(1), 21-31, 2000-01-01
… Especially, 4'-(2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzoazepine-6-carbonyl)-2-phenylbenzanilide monohydrochloride (18,YM087=conivaptan hydrochloride) exhibited potent binding affinity and AVP antagonist activity, after intravenous administration, for both V_<1A> …
NAID 110003635268